antibody

Epidermal Growth Factor Receptor (EGFr)

E3375-30

100 ug

monoclonal

mouse

nonconjugated

3G143

Epidermal Growth Factor Receptor (EGFr)

mouse

Mab

Antibodies

100 ug

3G143

IgG1,k

The epidermal growth factor receptor (EGFr) is a 170kD transmembrane protein consisting of an extracellular EGF-binding domain, a short transmembrane region, and an intracellular domain with ligand-activated tyrosine kinase activity. Two ligands can activate EGFr: epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-a). When TGF-a binds to EGFr, receptor tyrosine kinase activity is upregulated, producing phosphorylation and an increase in cytosolic calcium within target cells. This triggers increased synthesis of DNA and the proliferation and differentiation of target cells. TGF-a is an important effector of malignant transformation in a variety of cells. EGFr is expressed in many normal epithelial tissues, particularly in the basal layers of stratified epithelium and in squamous epithelium. Over-expression of EGFr has been observed in many types of neoplasia, as the result of gene amplification and/or increased protein transcription. EGFr over-expression has been detected in endometrial carcinoma, correlated with myometrial invasion, in lung neoplasms including metaplastic squamous epithelium, squamous cell carcinoma, adenocarcinoma, and neuroendocrine lung tumors, and in glioblastoma multiforme brain tumors. EGFr expression has also been reported in most head and neck carcinomas. Variable EGFr expression has been positively correlated with increasing tumor stage in transitional bladder, renal cell, and gastric carcinomas, and in inverse correlation to estrogen receptor (ER)-negative tumor status in breast carcinoma. Applications: Suitable for use in Immunohistochemistry, Flow Cytometry and Immunofluorescence. Other applications not tested. Recommended Dilutions: Flow Cytometry: 0.5-1ug/10e6 cells in 100ul Immunofluorescence: 1-2ug/ml Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections): 2-4ug/ml Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu

Human Epidermal Growth Factor Receptor derived from A431 cells.

Recognizes human Epidermal Growth Factor Receptor.

Purified by Protein A/G affinity chromatography.

Supplied as a liquid in 10mM PBS, 0.05% BSA, 0.05% sodium azide.

As reported

Product Type: Mab Isotype: IgG1,k Clone No: 3G143 Host: mouse Source: human Concentration: As reported Form: Supplied as a liquid in 10mM PBS, 0.05% BSA, 0.05% sodium azide. Purity: Purified by Protein A/G affinity chromatography. Immunogen: Human Epidermal Growth Factor Receptor derived from A431 cells. Specificity: Recognizes human Epidermal Growth Factor Receptor. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

FC IF IHC

-20°C

1. Cohen, S., et al. (1982) J. Biol. Chem. 257:1523–1539. 2. Chen, W.S., et al., (1989) Cell 59:33–43. 3. Pusztai, L., et al., (1993) J. Pathol. 169:9–14. 4. Ozane, B. and Richardson, C.S., (1986) J. Pathol. 149:191–201 . 5. Gusterson, B., et al. (1984) Cell Biol. Int. Rep. 8:649–658. 6. Damjanov, I., et al., (1986) Lab. Invest. 55(5):588–592. 7. Niikura, H., et al., (1996) Human Pathol. 27(3):282–289. 8. Rusch, V., et al., (1996) Ann. Thorac. Surg. 62:798–810. 9. Agosti, R.M., et al., (1992) Virchows Arch. Pathol. Anat. 420:321–325. 10. Christensen, M.E., (1998) Danish Med. Bull. 45(2):121–134. 11. Neal, D.E., et al., (1985) Lancet 1:366–368. 12. Toi, M., et al., (1989) Int. J. Cancer 43:220–225.

https://usbio-images.r.worldssl.net/prodimages/20/E3375-30_1.jpg